Recent news on Iressa

Silencing Cancer  -  Apr 27, 2007
Red Herring,By inhibiting a receptor on the surface of cancer cells, Tarceva and Iressa shut down the molecular signals inside lung cancer cells that tell them to grow

Treatment Strategy For Patients With Resistant Lung Tumors  -  May 2, 2007
Medical News Today (press release),..."We found that, for about 20 percent of patients with tumors that become resistant to Tarceva or Iressa, resistance is caused by the genetic activation of

Scientists Spot Mechanism Behind Lung Cancer Drug Resistance  -  Apr 26, 2007
Atlanta Journal Constitution (subscription),..."While patients respond to drugs like Iressa and Tarceva, the majority of patients become resistant to them. The cancers figure out a way to grow in the

Diagnosing Dendreon Postmortem  -  May 9, 2007
Motley FoolBesides AstraZeneca's (NYSE: AZN) cancer drug Iressa, which has turned into a big flop, no other compound has made it through the FDA on such a weak data

New drug combination for breast cancer patients  -  May 9, 2007
TopCancerNews.com,These 3 drugs are monoclonal antibodies which target certain aspects of tumours( pertuzumab; trastuzumab, also known as Herceptin; and gefitinib, or Iressa).

Mechanism produces resistance  -  Apr 26, 2007
France24,The mechanism was discovered in about 20 percent of patients with tumors that became resistant to Tarceva or Iressa, two commonly used targeted therapy

Shedding Light on Acquired Treatment Resistance in Lung Cancer  -  Apr 26, 2007
Cancerpage.com,NEW YORK APR 26, 2007 (Reuters Health) - New research indicates that lung cancers develop resistance to gefitinib (Iressa) through MET oncogene

Dendreon's Dilemma  -  May 9, 2007
Forbes,Five years ago, he warned against approving AstraZeneca's (nyse: AZN - news - people ) lung cancer pill Iressa because clinical data were not convincing.

BIO 2007: Return To Boston Underscores Industry's Growth  -  May 6, 2007
BioWorld Online,Gleevec (Novartis AG), Velcade (Millennium Inc.) and Iressa (AstraZeneca plc) have reached the market. The last time the annual convention was in Boston,

Drug combination helps certain breast cancer cases  -  May 1, 2007
Scientific AmericanThe third drug was gefitinib, sold by AstraZeneca under the brand name Iressa. All the drugs are monoclonal antibodies -- engineered human immune system

Drug combination helps certain breast cancer cases  -  May 1, 2007
ReutersL: Quote, Profile, Research under the brand name Iressa. All the drugs are monoclonal antibodies -- engineered human immune system proteins precisely

Astra could still spend "billions" on pipeline  -  Apr 30, 2007
Scotsman,AstraZeneca's recent poor track in bringing new drugs to market -- including the failures of Exanta, Iressa, Galida, NXY-059 and AGI-1067 in clinical trials

AstraZeneca to buy MedImmune _ and entry into vaccines market  -  Apr 25, 2007
NEPA News,...trial showing that its lung cancer drug Iressa did not help patients live longer and the rejection by US authorities of its anticoagulant Exanta.

AstraZeneca to buy MedImmune _ and entry into vaccines market  -  26 Apr 2007
NEPA News,...trial showing that its lung cancer drug Iressa did not help patients live longer and the rejection by US authorities of its anticoagulant Exanta.

Put Your Money Down  -  Apr 24, 2007
Corante,AZ has had a rough time of it the last few years, with several major clinical disappointments (one of which, Iressa, actually managed to stagger and lurch

Race, genes, and illness  -  Apr 20, 2007
International Herald Tribune,In the original Iressa studies, Japanese patients did respond better to the drug. Once the researchers controlled for other factors, though, the statistical

New methods for treating lung cancer cells that have become ...  -  Apr 24, 2007
News-Medical.net,The mutation was initially identified in one of Dr. Ma's patients who responded dramatically to Iressa prescribed for her terminal complication from her

Cancer Drugs A Key In MedImmune Purchase  -  Apr 23, 2007
Forbes,Over the past few years, an incredibly promising blood thinner and a stroke medicine both failed, and its cancer pill, Iressa, was pulled from wide use

AstraZeneca to buy MedImmune for $15.6B  -  Apr 23, 2007
BusinessWeek...trial showing that its lung cancer drug Iressa did not help patients live longer and the rejection by US authorities of its anticoagulant Exanta.

AstraZeneca to buy MedImmune for $15.6 billion  -  Apr 23, 2007
MarketWatchAstraZeneca's more high-profile failures have included blood thinner Exanta, lung-cancer drug Iressa, diabetes drug Galida and stroke drug NXY-059.

Study: Marijuana halts growth of lung cancer tumors  -  Apr 22, 2007
Indianapolis Star,Vectibix, which treats colon cancer; Genentech's Tarceva, approved for lung and pancreatic cancer; and AstraZeneca's Iressa, which treats lung cancer.

Infinity and MedImmune to Present Preclinical Data From Study of ...  -  Apr 10, 2007
PharmaLive.com (press release),NSCLC patients with mutations in EGFR have been found to benefit from drugs such as Tarceva(r) and Iressa(r) that block EGFR signaling.

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral ...  -  Apr 17, 2007
PharmaLive.com (press release),The molecularly targeted drugs - erlotinib (Tarceva(R)) and gefitinib (Iressa(R)) - inhibit EGFR kinase activity and are important therapies for patients

Dendreon's Positive Panel Surprise  -  Apr 3, 2007
Motley FoolIf Provenge gains full approval in May, it still would be the most unexpected drug approval since cancer treatment Iressa, considering the dearth of

Unapproved drugs spark life-and-death debate  -  Apr 1, 2007
USA TodayAt the time, Erbitux and Iressa were being tested against tumors with EGFR in the colon and lung, respectively. But her tumor was in the head and neck,

Dendreon Decision Could Mean FDA Shift  -  Mar 30, 2007
Forbes,For the FDA, there is always the worry of a repeat of AstraZeneca's (nyse: AZN - news - people ) cancer pill Iressa: The drug was approved on early data but

Japan seen as market for molecular target drugs  -  Mar 29, 2007
The Daily Yomiuri,For example, some patients being treated with Iressa, a cancer treatment drug made by British drugmaker AstraZeneca, died of pneumonia as a result of its

Drugs boss forces down the medicine  -  Mar 17, 2007
Times Online,A series of late-stage disappointments with important products — Iressa for cancer, Exanta for blood-thinning, Galida for diabetes and Cerovive for stroke

Is Dendreon Doomed?  -  Mar 19, 2007
Motley Fool...would be the least conservative decision displayed by the FDA since a panel voted in favor of approval for cancer treatment Iressa back in 2002.

Cathy Seipp talks about her cancer *  -  Mar 19, 2007
LA Observed,The only options so far are different kinds of chemotherapy or newer drugs like Iressa, and these have mostly worked for a while (they don’t for most people

AZs new PR&D centre leverages Indian chemistry expertise  -  Mar 23, 2007
DrugResearcher.com,The decision was predicated on the superior efficacy of Iressa (gefitinib), AstraZeneca's ill-fated treatment for lung cancer, in Asian over Western

Pharma firms won't swallow Astra patent pill  -  Mar 22, 2007
Rediff,Multinational drug major Astra Zeneca's attempts to have a patent protection for its branded lung cancer drug Iressa (geftinib) in the country have been

Native kinase profiling  -  Mar 21, 2007
DrugResearcher.com,While the majority of kinase inhibitors such as Tykerb, AstraZeneca's Iressa (gefitinib) and Bristol-Myers Squibb's Sprycel (dasatinib) all focus on various

A Personal Touch  -  Mar 19, 2007
Drug Discovery & Development,For agents like Tarceva, or Iressa, or Herceptin, there’s only a minority of patients who will respond—as low as 10%. So, the goal is to identify that 10%

GSK's new breast cancer drug approved  -  Mar 16, 2007
DrugResearcher.com,However, Tykerb is the first drug to target both HER2 and HER1, setting it apart from AstraZenenca's Iressa (gefitinib) - asmall molecule kinase inhibitor

Lung Cancer-Derived EGFR Mutants Exhibit Intrinsic Differences In ...  -  Mar 15, 2007
Medical News Today (press release),Structural examination of the inhibitor complexes, which included the drug gefitinib (Iressa), revealed that the mutations can affect the way the inhibitors

How Some Molecules Inhibit Growth Of Lung Cancer Cells Revealed By ...  -  Mar 15, 2007
Medical News Today (press release),They found that two inhibitors - the drug gefitinib (marketed as Iressa(R), and a compound called AEE788 - bind especially tightly to one of the mutated

New genes tied to cancers  -  Mar 8, 2007
Newsday,Drugs such as Novartis AG's Gleevec, AstraZeneca Plc's Iressa and Imclone Systems' Erbitux, target flawed protein kinases, often with fewer side effects

Finding of 100 cancer genes raises hope for drug therapy  -  Mar 7, 2007
Boston Globe,Gleevec and drugs such as AstraZeneca Plc's Iressa and Imclone Systems' Erbitux target flawed protein kinases, which often causes fewer side effects than

Iressa's efficacy over rival drugs unproved  -  Feb 6, 2007
The Japan Times,A recent study by an expert group under a Health, Labor and Welfare Ministry panel has failed to prove a higher potency of the cancer drug Iressa over an

Ruling may impact FDA's authority  -  Feb 18, 2007
The Republican,...and she failed to meet the clinical trial inclusion criteria for Iressa, an AstraZeneca cancer drug that later proved largely unsuccessful.

Gauge Regulator Opinion On Aspects Of Pharmacovigilance As It ...  -  Feb 2, 2007
PharmaLive.com (press release),The FDAs accelerated approval program is under intense scrutiny following the Vioxx debacle and the market withdrawal of AstraZenecas Iressa.

Infinity and MedImmune Initiate Phase I/II Clinical Trial of IPI ...  -  Feb 15, 2007
PipelineReview.com (press release),NSCLC patients with mutations in EGFR have been found to benefit from drugs such as Tarceva(r) and Iressa(r) that block EGFR signaling.

Cancer treatment takes step forward  -  Feb 21, 2007
Terre Haute Tribune Star,...therapies that specifically target cancerous cells, such as Herceptin, Avastin, Tarceva, Iressa, Gleevec and Sutent, according to the media release.

ImClone Opts Out Of UCB Deal To Develop CDP-791  -  Feb 6, 2007
BioWorld Online,Not so long ago, observers often likened an Erbitux/Iressa comparison to a Pepsi/Coke match, but that's starting to change, said Michael Bailey,

Terre Haute Cancer Center Teams up With Research Organization  -  Feb 20, 2007
Inside INdiana Business (press release),The network has conducted trials that have led to the approvals of such molecularly targeted therapies Herceptin, Avastin, Tarceva, Iressa,

Why Keeping Money in Introgen is a Fool's Game  -  Feb 20, 2007
Seeking Alpha,Iressa has also been studied in refractory recurrent SCCHN. In a phase 2 study, median survival was extended over the expected 6 months for that patient

Even Safety Needs Limits  -  Feb 18, 2007
Barron's (subscription)Some patients with advanced non-small-cell lung cancer respond to the drug Iressa, which, even if carefully administered and monitored, carries a certain

[Zoom In – New Technology]Targeting Cancer Cells Only  -  Feb 12, 2007
Etnews,How Far The Technology Advanced = The products for commercial use include 'Gleevec' for the chronic myeloid leukemia, 'Iressa' for lung cancer and

Stakeholder Insight: Non-Small Cell Lung Cancer - Challenging the ...  -  18 Jan 2007
Pharmaceutical Business Review...regimen loyalty in advanced disease. The Iressa-Tarceva battle is eagerly anticipated. Will Tarceva surpass Iressa's 'first-to-market' advantage in the US?

FDA warns of possible faulty test data  -  Jan 11, 2007
Science Daily (press release)FDA Statement On Iressa (December 24, 2004) -- The Food and Drug Administration (FDA) has learned from AstraZeneca that a large clinical trial comparing

Stakeholder Insight: Non-small cell lung cancer - Awareness and ...  -  Dec 19, 2006
Pharmaceutical Business ReviewThe Iressa-Tarceva battle is eagerly anticipated. Tarceva will have a successful EU launch, but it will not easily surpass Iressa's 'first-to-market'

Telik share price plummets after cancer drug failure  -  Jan 3, 2007
DrugResearcher.com,The company reported that in a Phase III trial called ASSIST-2, Telcyta did not improve overall survival compared to AstraZeneca's now-withdrawn Iressa

Targeted Cancer Drugs May Work By Disrupting Balance Of Cellular ...  -  Dec 28, 2006
Science Daily (press release)Again, kinase suppression, this time by application of Iressa, produced a rapid reduction in survival signals and eventual cell death as cell-death signals

Safe Practice Guidelines for Oral Chemotherapy Found Gravely Lacking  -  Jan 10, 2007
MedPage Today,The drugs included Xeloda (capecitabine), Cytoxan (cyclophosphamide), Iressa (gefitinib), Gleevec (imatinib), oral Rheumatrex (oral methotrexate),

AstraZeneca in diabetes deal with Bristol-Myers  -  Jan 11, 2007
Scotsman,...in a bid to strengthen its pipeline of new medicines following the failure of drugs such as Exanta for blood clots and Iressa for cancer.

Reality, Here In This Little Dish  -  Jan 10, 2007
Corante,AstraZeneca's drug Iressa is always useful to keep in mind. That one was going to be a huge hit, back when it was in development. But in real patients,

Dianne Feinstein: Forging a new plan to battle cancer  -  Jan 7, 2007
Sacramento Bee,There are dozens of targeted drug therapies for many different kinds of cancer: Iressa for those with small cell lung cancer, Avastin for colorectal cancer

Telik's Poor Drug-Trial Results  -  Dec 26, 2006
Wall Street Journal (subscription),Telik's Telcyta failed to improve survival in advanced non-small cell lung cancer patients compared with AstraZeneca PLC's Iressa.

Telik's Poor Drug-Trial Results  -  26 Dec 2006
Wall Street Journal (subscription),Telik's Telcyta failed to improve survival in advanced non-small cell lung cancer patients compared with AstraZeneca PLC's Iressa.

Health Canada Endorsed Important Safety Information on Iressa ...  -  Dec 12, 2006
DG NewsIressa is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Although Iressa is indicated for the treatment of locally advanced non-small

Stakeholder Insight: Non-small cell lung cancer - Awareness and ...  -  Dec 19, 2006
Pharmaceutical Business ReviewThe Iressa-Tarceva battle is eagerly anticipated. Tarceva will have a successful EU launch, but it will not easily surpass Iressa's 'first-to-market'

Stakeholder Insight: Non-Small Cell Lung Cancer - Challenging the ...  -  Dec 19, 2006
Pharmaceutical Business Review...regimen loyalty in advanced disease. The Iressa-Tarceva battle is eagerly anticipated. Will Tarceva surpass Iressa's 'first-to-market' advantage in the US?

Cost of cancer is a hard pill to swallow  -  Dec 12, 2006
Newsday,Those pills I was taking, called Iressa, had recently been approved by the Food and Drug Administration. For three months, I took them daily as part of my

Genzyme Introduces New Genetic Test to Complement Lung Cancer ...  -  Dec 6, 2006
Oxfordshire Bioscience Network (press release),TKI therapies, such as Tarceva (erlotinib) and IRESSA (gefitinib), are currently used in NSCLC patients who are refractory, or have failed,

Role of Nexavar® in NSCLC Reviewed  -  Nov 30, 2006
Cancer Consultants (press release),The results of a phase I clinical trial evaluated the combination of Nexavar and Iressa® (gefitinib) for the treatment of 32 patients with refractory or

New Genetic Test Predicts Response to Targeted Therapies  -  Dec 4, 2006
Genetic Engineering News (press release),...have been associated with resistance to certain drugs, including the tyrosine kinase inhibitors (TKIs) Tarceva® (erlotinib) and IRESSA® (gefitinib).

Genzyme launches lung-cancer gene test  -  Dec 4, 2006
United Press International...a marker linked to resistance to certain lung-cancer drugs, including the tyrosine kinase inhibitors Tarceva (erlotinib) and Iressa (gefitinib).

Glaxo boosts pipeline with spending spree  -  Dec 19, 2006
Scotsman,...say Glaxo's pipeline is very different to AstraZeneca's, which was left bare by the high-profile failure of products such as Exanta, Galida and Iressa.

AstraZeneca CEO says to cut disease focus -FT  -  Dec 16, 2006
ReutersIts latest new drug hope, stroke treatment NXY-059, failed in October, following earlier setbacks for anticoagulant Exanta, lung cancer pill Iressa and

Genzyme Introduces New Genetic Test and Gilead Stock Jumps  -  Dec 5, 2006
Financial News USA (press release),...currently used in treating this deadly form of cancer, including the tyrosine kinase inhibitors (TKIs) Tarceva® (erlotinib) and IRESSA® (gefitinib).

Analysts wary of drug maker's future  -  Dec 5, 2006
The News Journal,The following year, the company withdrew lung-cancer drug Iressa over questions about its effectiveness. In October, the company halted development of

The Body Hunters  Sep 23, 2006
By Jeanne Erdmann. In 2001, when a friend's lung cancer came back, she enrolled in a clinical trial testing Iressa. But the drug ... -St. Louis Post-Dispatch

Study uncovers mechanism of drug resistance in form of lung cancer  Sep 6, 2006
...led by Pasi Jänne, MD, PhD, found that many non-small cell lung cancer (NSCLC) patients who become resistant to targeted drugs such as Iressa® and Tarceva ... -EurekAlert

AstraZeneca Banks on Imaging to Reveal Next Big Drug (Update1)  Sep 4, 2006
Exanta in February. The lung cancer treatment Iressa has failed to reach the $1 billion in sales analysts expected. The company ... -Bloomberg

Schering, AstraZeneca in pact for cancer drug  Sep 15, 2006
...by AstraZeneca to rebuild its pipeline following past high-profile setbacks, including the failure in clinical trials of anti-coagulant Exanta, Iressa for lung ... -Scotsman

The Emerging Market  Sep 12, 2006
...their impact on overall health care costs.[1] Often referred to as "targeted" or "smart" drugs, they include Herceptin, Gleevec, Avastin, Erbitux, and Iressa. ... -American Enterprise Institute

Light Shed on Lung Cancer Drug-Resistance Mechanisms  Sep 6, 2006
...centers, reported that they have identified a different mechanism that appears to confer on non-small-cell lung tumors resistance to Iressa (gefitinib) and ... -MedPage Today

ASK THE DOCTOR  Sep 19, 2006
...kinase domain, which increases the likelihood of responding to drugs that block the EGFR pathway—such as Tarceva® (erlotinib) and Iressa® (gefitinib). ... -Cancer Consultants

Genetic map identifies nearly 200 cancer genes  Sep 11, 2006
...tumours and healthy cells. Newer drugs, such as Herceptin, Gleevec and Iressa target specific genes. The targeted therapies only ... -Stuff.co.nz

E-mail us your comments  Sep 9, 2006
A few new drugs like Gleevec and Iressa have had good results—but only for a tiny fraction of patients with highly specific forms of cancer, and even in ... -Newsweek

Cancer drug talk may get shriller  Aug 25, 2006
AstraZeneca’s Iressa (gefitinib tablets), used against non-small-cell lung cancer (NSCLC), also costs more than Rs 1 lakh per patient, while treatment of ... -Daily News & Analysis

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional